Q32 Bio Inc. (NASDAQ:QTTB) Given Average Rating of “Moderate Buy” by Brokerages

Q32 Bio Inc. (NASDAQ:QTTB) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $13.50.

A number of research analysts recently weighed in on QTTB shares. Cantor Fitzgerald started coverage on shares of Q32 Bio in a research note on Monday. They issued an “overweight” rating on the stock. Zacks Research lowered shares of Q32 Bio from a “strong-buy” rating to a “hold” rating in a research note on Monday. Mizuho started coverage on shares of Q32 Bio in a research note on Friday. They issued an “outperform” rating and a $14.00 price target on the stock. Weiss Ratings raised shares of Q32 Bio from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Monday, May 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Q32 Bio in a research note on Tuesday, May 5th.

Q32 Bio Trading Down 3.0%

Shares of Q32 Bio stock opened at $5.50 on Friday. The firm has a market capitalization of $93.28 million, a PE ratio of 2.07 and a beta of -0.05. Q32 Bio has a twelve month low of $1.35 and a twelve month high of $8.05. The firm’s 50-day moving average price is $6.08 and its 200 day moving average price is $4.39. The company has a current ratio of 5.36, a quick ratio of 5.36 and a debt-to-equity ratio of 0.04.

Q32 Bio (NASDAQ:QTTB) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.54) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.14. On average, sell-side analysts predict that Q32 Bio will post -2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other Q32 Bio news, CEO Jodie Pope Morrison sold 9,896 shares of the firm’s stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $4.51, for a total value of $44,630.96. Following the transaction, the chief executive officer directly owned 89,104 shares of the company’s stock, valued at $401,859.04. This trade represents a 10.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Over the last 90 days, insiders have sold 16,706 shares of company stock valued at $75,344. Company insiders own 40.00% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. Marshall Wace LLP acquired a new stake in shares of Q32 Bio during the 2nd quarter worth approximately $25,000. Acadian Asset Management LLC acquired a new stake in shares of Q32 Bio during the 1st quarter worth approximately $50,000. Two Sigma Investments LP acquired a new stake in shares of Q32 Bio during the 3rd quarter worth approximately $62,000. ADAR1 Capital Management LLC acquired a new stake in shares of Q32 Bio during the 4th quarter worth approximately $66,000. Finally, AQR Capital Management LLC acquired a new stake in shares of Q32 Bio during the 1st quarter worth approximately $68,000. 31.32% of the stock is owned by hedge funds and other institutional investors.

About Q32 Bio

Q32 Bio Inc, a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis.